Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 108,816 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Amneal Pharmaceuticals Inc | AMRX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.085 | -1.26% | 6.635 | 09:03:50 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 6.67 | 6.57 | 6.68 | 6.72 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume |
|---|---|---|---|---|
| 883 | 108,816 | US$ 6.66 | US$ 724,766 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 09:05:10 | 24 | US$ 6.64 | USD |
Amneal Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.8B | 307.01M | - | 2.41B | -83.99M | -0.27 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Amneal Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/20/2024 | 15:10 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 5/16/2024 | 14:13 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
| 5/14/2024 | 15:38 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 5/13/2024 | 15:15 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of.. |
| 5/08/2024 | 15:46 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 1/25/2024 | 06:30 | GlobeNewswire Inc. | Knight Therapeutics Enters into Exclusive License Agreement.. |
| 1/10/2024 | 06:03 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/05/2024 | 15:09 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 1/03/2024 | 15:36 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 1/03/2024 | 15:30 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AMRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
Amneal Pharmaceuticals Description
| Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. |
